多西紫杉醇联合顺铂、氟尿嘧啶治疗晚期胃癌的临床研究  

Clinical study in the first-line chemotherapy for advanced gastric cancer by DCF program

作　　者：杨蕴[1] 徐燕[1] 李玉芳[1] 陈长广[1] 周丽娜[1] 王李强[1] 

机构地区：[1]昆山市第一人民医院肿瘤科,江苏昆山215300

出　　处：《中国肿瘤外科杂志》2011年第5期294-297,301,共5页Chinese Journal of Surgical Oncology

摘　　要：目的对比观察DCF(多西紫杉醇、顺铂、氟尿嘧啶)方案及ECF(表阿霉素、顺铂、氟尿嘧啶)方案治疗晚期胃癌的疗效及毒副反应。方法 2006年2月至2010年4月共收集56例符合入组条件的晚期胃癌患者,随机分为DCF(28例)及ECF(28例)两组,每组至少完成两周期化疗后评价其疗效、毒副反应、总生存时间及中位生存期。结果 56例患者中的54例可评价疗效,其余1例因突发脑出血,1例因经济原因而终止治疗。总有效率(ORR):DCF组64.3%,ECF组46.2%,两组无显著性差异,DCF组与ECF组的总生存时间分别为(13.71±1.02)个月和(9.29±0.83)个月,中位生存期分别为14.2个月和8个月,经统计学比较差异有统计学意义。结论 DCF方案一线治疗晚期胃癌患者生存期明显提高,毒副反应可以耐受,值得临床进一步推广。Objective To observe the efficacy and adverse reactions in the treatment of advanced gastric cancer by DCF program （ docetaxel, eisplatin and fluorouracil） and ECF program （epirubicin, eisplatin and fluorouraeil）. Methods All 56 patients were divided into DCF group and ECF group by random, each group had 28 eases. We had observed efficacy, adverse, overall survival rate and median survival time after at least 2 completed treated cycles for two groups. Results 54 cases can be evaluated in 56 eases ,2 patients had quit out from treatment because of cerebral hemorrhage and economic reason. The objective response rate （ORR） was 64.3% , in the DCF group and 43.8% in the ECF group. The overall survival rate was 5.5 - 24.2 months in the DCF group and 3.6 - 19.6 months in the ECF group. The median survival time was 13.2 months in the DCF group and 9.6 months in the ECF group. The difference between the two groups was no significant in ORR and was significant in the overall survival rate and in the median survival time. Conclusions The DCF program as first-line chemotherapy for advanced gastric cancer improved the survival time, side effects can be tolerated and it will be popularized in the future.

关 键 词：晚期胃癌 DCF方案 ECF方案 多西紫杉醇 顺铂 氟尿嘧啶 表阿霉素 疗效比较 化疗毒副反应 

分 类 号：R735.2[医药卫生—肿瘤]